Article

Toric, nontoric IOLs provide full range of useful vision

Acrylic, apodized diffractive multifocal lenses achieve good uncorrected vision with a high rate of spectacle independence in two prospective studies.

 

Chicago-Results from two prospective studies demonstrate that patients with either the toric or nontoric versions of an acrylic, apodized diffractive multifocal IOL (AcrySof IQ ReSTOR +3.0 D Multifocal Toric and Multifocal IOLs, Alcon) implanted bilaterally achieve good uncorrected vision for near, intermediate, and distance along with a high rate of spectacle independence, said Michael C. Knorz, MD, at Refractive Surgery 2012 during the annual meeting of the American Academy of Ophthalmology.

Dr. Knorz is professor of ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. He summarized findings from two multicenter studies. In one, 44 patients with preoperative corneal astigmatism ≥0.75 D and ≤2.5 D had the toric version of the multifocal IOL implanted using one of three available models, which correct between 1.0 and 2.0 D of astigmatism at the corneal plane. The study of the nontoric multifocal IOL included 138 patients who had up to 1 D of corneal astigmatism preoperatively. In both cohorts, outcomes were analyzed for data collected at the 6-month visit.

Mean near logMAR UCVA measured at 40 cm in the toric and nontoric groups was 0.07 and 0.10, respectively; at preferred distance (39 cm for toric and 37 cm for nontoric), mean near logMAR UCVA values were 0.05 and 0.09, respectively. In distance UCVA testing, mean logMAR UCVA was 0.05 for the patients with the toric lenses and 0.03 in the nontoric study. Intermediate UCVA was measured at 50, 60, and 70 cm, and logMAR values for those distances were 0.05, 0.09, and 0.15, respectively, for the toric group and 0.13, 0.16, and 0.21, respectively for the nontoric group.

 “As expected, the best intermediate visual acuity results were achieved at the closer distance because there is no real intermediate focus with this lens. However, patients still had useful acuity at 70 cm with both the toric and nontoric designs,” Dr. Knorz said.

When asked about the need for spectacles, 90% of patients in the toric multifocal IOL study said they never needed glasses, while 78% of patients receiving the nontoric version of the multifocal IOL reported not needing glasses at all. With just a few exceptions, the remaining patients in both cohorts said they wore glasses only sometimes.

The toric version of the AcrySof multifocal IOL is not FDA approved. Dr. Knorz is a consultant for Alcon.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.